 | • レポートコード：MRC2102QY6987 • 出版社/出版日： / 2021年1月 • レポート形態：英文、PDF、134ページ • 納品方法：Eメール（受注後2~3営業日） • 産業分類：医薬品、医療 |
| Single User | ￥600,000 (USD4,000) | ▷ お問い合わせ |
| Multi User | ￥900,000 (USD6,000) | ▷ お問い合わせ |
| Enterprise License | ￥1,200,000 (USD8,000) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYリサーチ社の本調査レポートでは、世界の特発性肺線維症治療薬市場について種類別（糖質コルチコイド、免疫抑制剤、その他）、用途別（病院、診療所、その他）、地域別（米国、ヨーロッパ、中国、日本、東南アジア、インド）に区分して調査し、纏めました。2015年～2026年までの市場規模予測、主要プレイヤーの競争状況・市場シェア・企業情報、製造コスト分析、販売チャネル・流通業者・顧客情報、市場動向・機会・課題などのマーケットデータが記載されています。市場予測データは新型コロナウイルスの影響を反映させました。 ・特発性肺線維症治療薬市場の概要 ・世界の主要地域別特発性肺線維症治療薬市場規模2015-2026 ・主要プレイヤーの競争状況・市場シェア ・世界の特発性肺線維症治療薬市場規模2015-2026：種類別（糖質コルチコイド、免疫抑制剤、その他） ・世界の特発性肺線維症治療薬市場規模2015-2026：用途別（病院、診療所、その他） ・特発性肺線維症治療薬の米国市場規模2015-2020 ・特発性肺線維症治療薬のヨーロッパ市場規模2015-2020 ・特発性肺線維症治療薬の中国市場規模2015-2020 ・特発性肺線維症治療薬の日本市場規模2015-2020 ・特発性肺線維症治療薬の東南アジア市場規模2015-2020 ・特発性肺線維症治療薬のインド市場規模2015-2020 ・主要プレイヤーの企業情報：事業概要・売上・企業動向 ・特発性肺線維症治療薬の製造コスト分析 ・販売チャネル、流通業者、顧客 ・特発性肺線維症治療薬の市場動向・機会・課題 ・調査の結論 |
Market Analysis and Insights: Global Idiopathic Pulmonary Fibrosis Drug Market
The global Idiopathic Pulmonary Fibrosis Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
Global Idiopathic Pulmonary Fibrosis Drug Scope and Market Size
The global Idiopathic Pulmonary Fibrosis Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Idiopathic Pulmonary Fibrosis Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2015-2026.
Segment by Type, the Idiopathic Pulmonary Fibrosis Drug market is segmented into
Glucocorticoid
Immunosuppressive Agent
Others
Segment by Application, the Idiopathic Pulmonary Fibrosis Drug market is segmented into
Hospital
Clinic
Other
The Idiopathic Pulmonary Fibrosis Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Idiopathic Pulmonary Fibrosis Drug market is segmented into United States, Europe, China, Japan, Southeast Asia, India and Rest of World.
The report includes region-wise market size for the period 2015-2026. It also includes market size and forecast by players, by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Idiopathic Pulmonary Fibrosis Drug Market Share Analysis
Idiopathic Pulmonary Fibrosis Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Idiopathic Pulmonary Fibrosis Drug business, the date to enter into the Idiopathic Pulmonary Fibrosis Drug market, Idiopathic Pulmonary Fibrosis Drug product introduction, recent developments, etc.
The major vendors covered:
Roche
Boehringer Ingelheim
Beijing Continent Pharmaceutical
Cipla
Shionogi
1 Idiopathic Pulmonary Fibrosis Drug Market Overview
1.1 Idiopathic Pulmonary Fibrosis Drug Product Scope
1.2 Idiopathic Pulmonary Fibrosis Drug Segment by Type
1.2.1 Global Idiopathic Pulmonary Fibrosis Drug Sales by Type (2020-2026)
1.2.2 Glucocorticoid
1.2.3 Immunosuppressive Agent
1.2.4 Others
1.3 Idiopathic Pulmonary Fibrosis Drug Segment by Application
1.3.1 Global Idiopathic Pulmonary Fibrosis Drug Sales Comparison by Application (2020-2026)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Idiopathic Pulmonary Fibrosis Drug Market Estimates and Forecasts (2015-2026)
1.4.1 Global Idiopathic Pulmonary Fibrosis Drug Sales Growth Rate (2015-2026)
1.4.2 Global Idiopathic Pulmonary Fibrosis Drug Revenue and Growth Rate (2015-2026)
1.4.3 Global Idiopathic Pulmonary Fibrosis Drug Price Trends (2015-2026)
2 Idiopathic Pulmonary Fibrosis Drug Estimate and Forecast by Region
2.1 Global Idiopathic Pulmonary Fibrosis Drug Market Size by Region: 2015 VS 2020 VS 2026
2.2 Global Idiopathic Pulmonary Fibrosis Drug Retrospective Market Scenario by Region (2015-2020)
2.2.1 Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Region (2015-2020)
2.2.2 Global Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Region (2015-2020)
2.3 Global Idiopathic Pulmonary Fibrosis Drug Market Estimates and Forecasts by Region (2021-2026)
2.3.1 Global Idiopathic Pulmonary Fibrosis Drug Sales Estimates and Forecasts by Region (2021-2026)
2.3.2 Global Idiopathic Pulmonary Fibrosis Drug Revenue Forecast by Region (2021-2026)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 United States Idiopathic Pulmonary Fibrosis Drug Estimates and Projections (2015-2026)
2.4.2 Europe Idiopathic Pulmonary Fibrosis Drug Estimates and Projections (2015-2026)
2.4.3 China Idiopathic Pulmonary Fibrosis Drug Estimates and Projections (2015-2026)
2.4.4 Japan Idiopathic Pulmonary Fibrosis Drug Estimates and Projections (2015-2026)
2.4.5 Southeast Asia Idiopathic Pulmonary Fibrosis Drug Estimates and Projections (2015-2026)
2.4.6 India Idiopathic Pulmonary Fibrosis Drug Estimates and Projections (2015-2026)
3 Global Idiopathic Pulmonary Fibrosis Drug Competition Landscape by Players
3.1 Global Top Idiopathic Pulmonary Fibrosis Drug Players by Sales (2015-2020)
3.2 Global Top Idiopathic Pulmonary Fibrosis Drug Players by Revenue (2015-2020)
3.3 Global Idiopathic Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Pulmonary Fibrosis Drug as of 2019)
3.4 Global Idiopathic Pulmonary Fibrosis Drug Average Price by Company (2015-2020)
3.5 Manufacturers Idiopathic Pulmonary Fibrosis Drug Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3.7 Primary Interviews with Key Idiopathic Pulmonary Fibrosis Drug Players (Opinion Leaders)
4 Global Idiopathic Pulmonary Fibrosis Drug Market Size by Type
4.1 Global Idiopathic Pulmonary Fibrosis Drug Historic Market Review by Type (2015-2020)
4.1.1 Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
4.1.2 Global Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Type (2015-2020)
4.1.3 Global Idiopathic Pulmonary Fibrosis Drug Price by Type (2015-2020)
4.2 Global Idiopathic Pulmonary Fibrosis Drug Market Estimates and Forecasts by Type (2021-2026)
4.2.1 Global Idiopathic Pulmonary Fibrosis Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Idiopathic Pulmonary Fibrosis Drug Revenue Forecast by Type (2021-2026)
4.2.3 Global Idiopathic Pulmonary Fibrosis Drug Price Forecast by Type (2021-2026)
5 Global Idiopathic Pulmonary Fibrosis Drug Market Size by Application
5.1 Global Idiopathic Pulmonary Fibrosis Drug Historic Market Review by Application (2015-2020)
5.1.1 Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)
5.1.2 Global Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Application (2015-2020)
5.1.3 Global Idiopathic Pulmonary Fibrosis Drug Price by Application (2015-2020)
5.2 Global Idiopathic Pulmonary Fibrosis Drug Market Estimates and Forecasts by Application (2021-2026)
5.2.1 Global Idiopathic Pulmonary Fibrosis Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Idiopathic Pulmonary Fibrosis Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Idiopathic Pulmonary Fibrosis Drug Price Forecast by Application (2021-2026)
6 United States Idiopathic Pulmonary Fibrosis Drug Market Facts & Figures
6.1 United States Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2015-2020)
6.2 United States Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
6.3 United States Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)
7 Europe Idiopathic Pulmonary Fibrosis Drug Market Facts & Figures
7.1 Europe Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2015-2020)
7.2 Europe Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
7.3 Europe Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)
8 China Idiopathic Pulmonary Fibrosis Drug Market Facts & Figures
8.1 China Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2015-2020)
8.2 China Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
8.3 China Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)
9 Japan Idiopathic Pulmonary Fibrosis Drug Market Facts & Figures
9.1 Japan Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (3015-3030)
9.2 Japan Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
9.3 Japan Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)
10 Southeast Asia Idiopathic Pulmonary Fibrosis Drug Market Facts & Figures
10.1 Southeast Asia Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2015-2020)
10.2 Southeast Asia Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
10.3 Southeast Asia Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)
11 India Idiopathic Pulmonary Fibrosis Drug Market Facts & Figures
11.1 India Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2015-2020)
11.2 India Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
11.3 India Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)
12 Company Profiles and Key Figures in Idiopathic Pulmonary Fibrosis Drug Business
12.1 Roche
12.1.1 Roche Corporation Information
12.1.2 Roche Business Overview
12.1.3 Roche Idiopathic Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
12.1.4 Roche Idiopathic Pulmonary Fibrosis Drug Products Offered
12.1.5 Roche Recent Development
12.2 Boehringer Ingelheim
12.2.1 Boehringer Ingelheim Corporation Information
12.2.2 Boehringer Ingelheim Business Overview
12.2.3 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
12.2.4 Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Drug Products Offered
12.2.5 Boehringer Ingelheim Recent Development
12.3 Beijing Continent Pharmaceutical
12.3.1 Beijing Continent Pharmaceutical Corporation Information
12.3.2 Beijing Continent Pharmaceutical Business Overview
12.3.3 Beijing Continent Pharmaceutical Idiopathic Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
12.3.4 Beijing Continent Pharmaceutical Idiopathic Pulmonary Fibrosis Drug Products Offered
12.3.5 Beijing Continent Pharmaceutical Recent Development
12.4 Cipla
12.4.1 Cipla Corporation Information
12.4.2 Cipla Business Overview
12.4.3 Cipla Idiopathic Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
12.4.4 Cipla Idiopathic Pulmonary Fibrosis Drug Products Offered
12.4.5 Cipla Recent Development
12.5 Shionogi
12.5.1 Shionogi Corporation Information
12.5.2 Shionogi Business Overview
12.5.3 Shionogi Idiopathic Pulmonary Fibrosis Drug Sales, Revenue and Gross Margin (2015-2020)
12.5.4 Shionogi Idiopathic Pulmonary Fibrosis Drug Products Offered
12.5.5 Shionogi Recent Development
…
13 Idiopathic Pulmonary Fibrosis Drug Manufacturing Cost Analysis
13.1 Idiopathic Pulmonary Fibrosis Drug Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Idiopathic Pulmonary Fibrosis Drug
13.4 Idiopathic Pulmonary Fibrosis Drug Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Idiopathic Pulmonary Fibrosis Drug Distributors List
14.3 Idiopathic Pulmonary Fibrosis Drug Customers
15 Market Dynamics
15.1 Idiopathic Pulmonary Fibrosis Drug Market Trends
15.2 Idiopathic Pulmonary Fibrosis Drug Opportunities and Drivers
15.3 Idiopathic Pulmonary Fibrosis Drug Market Challenges
15.4 Idiopathic Pulmonary Fibrosis Drug Market Restraints
15.5 Porter’s Five Forces Analysis
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
Table 1. Global Idiopathic Pulmonary Fibrosis Drug Sales (K MT) Growth Rate by Type (2020-2026) (US$ Million)
Table 2. Global Idiopathic Pulmonary Fibrosis Drug Sales (K MT) Comparison by Application (2020-2026) (US$ Million)
Table 3. Global Market Idiopathic Pulmonary Fibrosis Drug Market Size (US$ Million) by Region:2015 VS 2020 &2026
Table 4. Global Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Region (2015-2020)
Table 5. Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Region (2015-2020)
Table 6. Global Idiopathic Pulmonary Fibrosis Drug Revenue (US$ Million) Market Share by Region (2015-2020))
Table 7. Global Idiopathic Pulmonary Fibrosis Drug Revenue Share by Region (2015-2020)
Table 8. Global Idiopathic Pulmonary Fibrosis Drug Sales (K MT) Forecast by Region (2021-2026)
Table 9. Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share Forecast by Region (2021-2026)
Table 10. Global Idiopathic Pulmonary Fibrosis Drug Revenue (US$ Million) Forecast by Region (2021-2026)
Table 11. Global Idiopathic Pulmonary Fibrosis Drug Revenue Share Forecast by Region (2021-2026)
Table 12. Global Idiopathic Pulmonary Fibrosis Drug (K MT) of Key Companies (2015-2020)
Table 13. Global Idiopathic Pulmonary Fibrosis Drug Sales Share by Company (2015-2020)
Table 14. Global Idiopathic Pulmonary Fibrosis Drug Revenue (US$ Million) by Company (2015-2020)
Table 15. Global Idiopathic Pulmonary Fibrosis Drug Revenue Share by Company (2015-2020)
Table 16. Global Idiopathic Pulmonary Fibrosis Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Idiopathic Pulmonary Fibrosis Drug as of 2019)
Table 17. Global Idiopathic Pulmonary Fibrosis Drug Average Price (USD/MT) of Key Company (2015-2020)
Table 18. Manufacturers Idiopathic Pulmonary Fibrosis Drug Manufacturing Sites and Area Served
Table 19. Manufacturers Idiopathic Pulmonary Fibrosis Drug Product Type
Table 20. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 21. Main Points Interviewed from Key Idiopathic Pulmonary Fibrosis Drug Players
Table 22. Global Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Type (2015-2020)
Table 23. Global Idiopathic Pulmonary Fibrosis Drug Sales Share by Type (2015-2020)
Table 24. Global Idiopathic Pulmonary Fibrosis Drug Revenue (US$ Million) Market Share by Type (2015-2020)
Table 25. Global Idiopathic Pulmonary Fibrosis Drug Price (K MT) by Type (2015-2020)
Table 26. Global Idiopathic Pulmonary Fibrosis Drug Sales Share by Type (2021-2026)
Table 27. Global Idiopathic Pulmonary Fibrosis Drug Revenue (US$ Million) Market Share by Type (2021-2026)
Table 28. Global Idiopathic Pulmonary Fibrosis Drug Revenue Share by Type (2021-2026)
Table 29. Global Idiopathic Pulmonary Fibrosis Drug Price (K MT) by Type (2021-2026)
Table 30. Global Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Application (2015-2020)
Table 31. Global Idiopathic Pulmonary Fibrosis Drug Sales Share by Application (2015-2020)
Table 32. Global Idiopathic Pulmonary Fibrosis Drug Revenue (US$ Million) Market Share by Application (2015-2020)
Table 33. Global Idiopathic Pulmonary Fibrosis Drug Price (K MT) by Application (2015-2020)
Table 34. Global Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Application (2021-2026)
Table 35. Global Idiopathic Pulmonary Fibrosis Drug Sales Share by Application (2021-2026)
Table 36. Global Idiopathic Pulmonary Fibrosis Drug Revenue (US$ Million) Market Share by Application (2021-2026)
Table 37. Global Idiopathic Pulmonary Fibrosis Drug Revenue Share by Application (2021-2026)
Table 38. Global Idiopathic Pulmonary Fibrosis Drug Price (K MT) by Application (2021-2026)
Table 39. United States Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Company (2015-2020)
Table 40. United States Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2015-2020)
Table 41. United States Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Type (2015-2020)
Table 42. United States Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
Table 43. United States Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Application (2015-2020)
Table 44. United States Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)
Table 45. Europe Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Company (2015-2020)
Table 46. Europe Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2015-2020)
Table 47. Europe Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Type (2015-2020)
Table 48. Europe Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
Table 49. Europe Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Application (2015-2020)
Table 50. Europe Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
Table 51. China Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Company (2015-2020)
Table 52. China Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2015-2020)
Table 53. China Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Type (2015-2020)
Table 54. China Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
Table 55. China Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Application (2015-2020)
Table 56. China Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)
Table 57. Japan Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Company (2015-2020)
Table 58. Japan Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2015-2020)
Table 59. Japan Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Type (2015-2020)
Table 60. Japan Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
Table 61. Japan Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Application (2015-2020)
Table 62. Japan Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)
Table 63. Southeast Asia Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Company (2015-2020)
Table 64. Southeast Asia Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2015-2020)
Table 65. Southeast Asia Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Type (2015-2020)
Table 66. Southeast Asia Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
Table 67. Southeast Asia Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Type (2015-2020)
Table 68. Southeast Asia Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)
Table 69. India Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Company (2015-2020)
Table 70. India Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company (2015-2020)
Table 71. India Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Type (2015-2020)
Table 72. India Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type (2015-2020)
Table 73. India Idiopathic Pulmonary Fibrosis Drug Sales (K MT) by Application (2015-2020)
Table 74. India Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application (2015-2020)
Table 75. Roche Corporation Information
Table 76. Roche Description and Business Overview
Table 77. Roche Idiopathic Pulmonary Fibrosis Drug Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 78. Roche Idiopathic Pulmonary Fibrosis Drug Product
Table 79. Roche Recent Development
Table 80. Boehringer Ingelheim Corporation Information
Table 81. Boehringer Ingelheim Description and Business Overview
Table 82. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Drug Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 83. Boehringer Ingelheim Idiopathic Pulmonary Fibrosis Drug Product
Table 84. Boehringer Ingelheim Recent Development
Table 85. Beijing Continent Pharmaceutical Corporation Information
Table 86. Beijing Continent Pharmaceutical Description and Business Overview
Table 87. Beijing Continent Pharmaceutical Idiopathic Pulmonary Fibrosis Drug Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 88. Beijing Continent Pharmaceutical Idiopathic Pulmonary Fibrosis Drug Product
Table 89. Beijing Continent Pharmaceutical Recent Development
Table 90. Cipla Corporation Information
Table 91. Cipla Description and Business Overview
Table 92. Cipla Idiopathic Pulmonary Fibrosis Drug Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 93. Cipla Idiopathic Pulmonary Fibrosis Drug Product
Table 94. Cipla Recent Development
Table 95. Shionogi Corporation Information
Table 96. Shionogi Description and Business Overview
Table 97. Shionogi Idiopathic Pulmonary Fibrosis Drug Sales (K MT), Revenue (Million USD), Price (USD/MT) and Gross Margin (2015-2020)
Table 98. Shionogi Idiopathic Pulmonary Fibrosis Drug Product
Table 99. Shionogi Recent Development
Table 100. Production Base and Market Concentration Rate of Raw Material
Table 101. Key Suppliers of Raw Materials
Table 102. Idiopathic Pulmonary Fibrosis Drug Distributors List
Table 103. Idiopathic Pulmonary Fibrosis Drug Customers List
Table 104. Idiopathic Pulmonary Fibrosis Drug Market Key Trends
Table 105. Idiopathic Pulmonary Fibrosis Drug Key Opportunities and Drivers
Table 106. Idiopathic Pulmonary Fibrosis Drug Market Challenges
Table 107. Research Programs/Design for This Report
Table 108. Key Data Information from Secondary Sources
Table 109. Key Data Information from Primary Sources
List of Figures
Figure 1. Idiopathic Pulmonary Fibrosis Drug Product Picture
Figure 2. Global Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type in 2020 & 2026
Figure 3. Type I Product Picture
Figure 4. Type II Product Picture
Figure 5. Global Idiopathic Pulmonary Fibrosis Drug Market Share by Application in 2020 & 2026
Figure 6. Hospital Examples
Figure 7. Clinic Examples
Figure 8. Other Examples
Figure 9. Global Idiopathic Pulmonary Fibrosis Drug Sales (K MT) Growth Rate (2015-2026)
Figure 10. Global Idiopathic Pulmonary Fibrosis Drug Revenue (US$ Million) Growth Rate (2015-2026)
Figure 11. Global Idiopathic Pulmonary Fibrosis Drug Price Trends Growth Rate (2015-2026) (USD/MT)
Figure 12. Global Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Region: 2015 VS 2020
Figure 13. Global Idiopathic Pulmonary Fibrosis Drug Revenue Market Share by Region: 2021 VS 2026
Figure 14. United States Idiopathic Pulmonary Fibrosis Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 15. United States Idiopathic Pulmonary Fibrosis Drug Sales (K MT) Growth Rate (2015-2026)
Figure 16. Europe Idiopathic Pulmonary Fibrosis Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 17. Europe Idiopathic Pulmonary Fibrosis Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 18. China Idiopathic Pulmonary Fibrosis Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 19. China Idiopathic Pulmonary Fibrosis Drug Sales (Million USD) and Growth Rate (2015-2026)
Figure 20. Japan Idiopathic Pulmonary Fibrosis Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 21. Japan Idiopathic Pulmonary Fibrosis Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 22. Southeast Asia Idiopathic Pulmonary Fibrosis Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 23. Southeast Asia Idiopathic Pulmonary Fibrosis Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 24. India Idiopathic Pulmonary Fibrosis Drug Revenue (Million USD) Growth Rate (2015-2026)
Figure 25. India Idiopathic Pulmonary Fibrosis Drug Sales (Million USD) Growth Rate (2015-2026)
Figure 26. Global 5 Largest Idiopathic Pulmonary Fibrosis Drug Players Market Share by Revenue in Idiopathic Pulmonary Fibrosis Drug 2015 & 2019
Figure 27. Idiopathic Pulmonary Fibrosis Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 28. Global Idiopathic Pulmonary Fibrosis Drug Revenue Share by Type (2015-2020)
Figure 29. Global Idiopathic Pulmonary Fibrosis Drug Revenue Growth Rate by Type in 2015 & 2019
Figure 30. Global Idiopathic Pulmonary Fibrosis Drug Revenue Share by Application (2015-2020)
Figure 31. Global Idiopathic Pulmonary Fibrosis Drug Revenue Growth Rate by Application in 2015 & 2019
Figure 32. United States Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type in 2019
Figure 33. United States Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type in 2019
Figure 34. Europe Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company in 2019
Figure 35. Europe Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type in 2019
Figure 36. Europe Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application in 2019
Figure 37. China Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company in 2019
Figure 38. China Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type in 2019
Figure 39. China Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application in 2019
Figure 40. Japan Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company in 2019
Figure 41. Japan Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type in 2019
Figure 42. Japan Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application in 2019
Figure 43. Southeast Asia Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company in 2019
Figure 44. Southeast Asia Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type in 2019
Figure 45. Southeast Asia Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application in 2019
Figure 46. India Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Company in 2019
Figure 47. India Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Type in 2019
Figure 48. India Idiopathic Pulmonary Fibrosis Drug Sales Market Share by Application in 2019
Figure 49. Key Raw Materials Price Trend
Figure 50. Manufacturing Cost Structure of Idiopathic Pulmonary Fibrosis Drug
Figure 51. Manufacturing Process Analysis of Idiopathic Pulmonary Fibrosis Drug
Figure 52. Idiopathic Pulmonary Fibrosis Drug Industrial Chain Analysis
Figure 53. Channels of Distribution
Figure 54. Distributors Profiles
Figure 55. Porter's Five Forces Analysis
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
肺塞栓症治療薬の世界市場レポート2020 Market Analysis and Insights: Global Pulmonary Embolism Drug Market The global Pulmonary Embolism Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Pulmonary Embolism Drug Scope and Market Size The global Pulmonary E…- 肺高血圧症治療薬の世界市場レポート2020 Market Analysis and Insights: Global Pulmonary Hypertension Drug Market The global Pulmonary Hypertension Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Pulmonary Hypertension Drug Scope and Market Size The global…
- 肺用ドラッグデリバリーデバイス/システムの世界市場レポート2020 Pulmonary Drug Delivery Devices/Systems include metered dose inhalers,dry powder inhalers,nebulizers and accessories. North America dominates the dominant drug delivery devices/systems market position. Major local pharmaceutical and medical device manufacturers, advanced medical infrastructure, popu…
- 肺用ドラッグデリバリーシステムの世界市場レポート2020 Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent cap…
- 経カテーテル肺動脈弁（TPV）の世界市場レポート2020 Market Analysis and Insights: Global Transcatheter Pulmonary Valve (TPV) Market The global Transcatheter Pulmonary Valve (TPV) market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026. Global Transcatheter Pulmonary Valve (TPV) Scope an…